Published in TB and Outbreaks Week, February 21st, 2006
According to a recently published study from France, "One of the main issues raised by the management of external genital warts is their potential risk of recurrence. However, nearly all studies assessing recurrences have been conducted with a 3-month follow-up.
"Since the latency of the human papillomavirus is long, such 3 month follow-up might be too short to detect the true recurrence rate. We, therefore, conducted a study evaluating patients with external genital warts, treated with an immune response modifier, 558 imiquimod cream, and followed up to 6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week